SAN MATEO, Calif. — RapidAI, a global leader in enterprise imaging and deep clinical artificial intelligence, announced that the U.S. Food and Drug Administration has cleared five new imaging modules: Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH and Rapid Aortic for measurement. The additional modules significantly expand the Rapid Enterprise Platform, advancing radiology precision while strengthening neurology and vascular care.
RapidAI develops deep clinical AI designed to go beyond basic triage by reducing cognitive burden on radiologists, supporting acute intervention and transfer decisions, and improving longer-term patient management. These latest clearances reinforce the company’s approach of enabling clinicians to characterize, quantify, visualize and track disease progression rather than simply flag suspected findings.
Rapid DeltaFuse is designed to improve longer-term patient monitoring by automatically aligning and co-registering serial non-contrast head CT scans to help visualize subtle changes such as acute or chronic hemorrhage, ventricular changes or masses. Rapid LMVO expands comprehensive brain coverage on CTA to support ischemic stroke care across anterior, posterior, basilar and distal territories. Rapid MLS detects and quantifies suspected midline shift with objective measurements to help clinicians identify meaningful changes earlier. Rapid OH identifies suspected obstructive hydrocephalus rapidly by detecting cerebrospinal fluid accumulation, and also qualifies for the CMS New Technology Add-on Payment designation. Rapid Aortic analyzes CT scans that include the aorta to help clinicians identify and monitor pathology using guideline-based measurements and automated 3D visualization.
“The FDA clearances of these solutions underscore our commitment to deep clinical AI and reducing cognitive burden for radiologists, as well as supporting superior decision-making and outcomes,” said Karim Karti, CEO of RapidAI. “RapidAI algorithms help set new standards by enabling radiologists to practice at the top of their license, reducing cognitive burden, and improving clinical decision-making for better outcomes in both acute and long-term settings.”
Physicians working with the technology report reduced interpretation time, increased efficiency and improved confidence in identifying critical findings.
All new modules are integrated into Rapid Edge Cloud, RapidAI’s cloud-first IT platform with on-premise capability, and are compatible with Rapid Navigator Pro along with the company’s mobile and web applications. The expanded platform is designed to provide a seamless and secure experience across PACS, EHR and reporting systems, enabling radiologists to compare and act on findings without workflow disruption.
